Clindamycin vs Amoxicillin for Dental Work: Key Risks
April 22, 2026 · Updated Aug 15, 2026
The antibiotic US dentists most often prescribe for penicillin-allergic patients drives Clostridioides difficile deaths. The 2021 American Heart Association prophylaxis guideline is narrower than the prescribing pattern. Three questions turn the evidence into a patient-side protocol.
The antibiotic US dentists most often prescribe for penicillin-allergic patients drives Clostridioides difficile deaths. The 2021 American Heart Association prophylaxis guideline is narrower than the prescribing pattern. Three questions turn the evidence into a patient-side protocol.
Clindamycin, the antibiotic US dentists most often choose for patients with penicillin allergies, causes 2.9 fatal adverse drug reactions per million prescriptions. Amoxicillin causes 0.1. The 29-fold difference was documented in a 2019 analysis of England's National Health Service prescribing data led by Martin Thornhill at the University of Sheffield and Peter Lockhart at Atrium Health Carolinas Medical Center (Journal of Dental Research, PMID 31314998). The deaths trace to Clostridioides difficile, the bacterial infection that colonizes the gut when clindamycin clears the beneficial flora.
Two recent stories in the Black health press have put names to what that statistic looks like in practice. A Black grandmother, Dolores Hernandez Owens, died after a clindamycin course prescribed for dental work. A Black father, Davon Vanterpool, lost limbs to sepsis after dental bleeding. Those are one-family stories. Behind them is a prescribing pattern that national regulators, professional societies, and academic dentistry have been trying to move for a decade.
The US is the outlier on prescribing volume
US dentists prescribe antibiotics at nearly twice the rate of Australian dentists. A 2022 cross-national comparison in Infection Control and Hospital Epidemiology, led by Wendy Thompson and Katie Suda, examined outpatient dental antibiotic prescriptions in 2017 across Australia, England, the United States, and British Columbia (PMID 33818323). The US rate was the highest of the four jurisdictions. Clindamycin was the second-most-prescribed antibiotic in US dental practice. Metronidazole filled that slot in Australia and England; US dentists have not made the same shift.
The 2021 AHA guideline is narrower than the prescribing pattern
The American Heart Association reviewed its 2007 endocarditis prophylaxis recommendations in a 2021 scientific statement adapted for the American Dental Association's members (Wilson et al., Journal of the American Dental Association, PMID 34711348). The review's conclusion: no changes to 2007. Prophylactic antibiotics before invasive dental procedures are indicated only for a narrow list of cardiac conditions, including prosthetic heart valves, prior infective endocarditis, specific congenital heart disease, and cardiac transplant recipients with valvulopathy. The general dental patient, the one with a routine dental-work appointment and no qualifying cardiac condition, is not on that list.
The gap between the 2021 guideline and US prescribing is the story.
No study has reported Black-specific dental outcomes
No peer-reviewed study has stratified dental-antibiotic outcomes by Black versus non-Black patients in the US. The population-level work cited above is English NHS data (Thornhill 2019) and North American and European data (Thompson 2022), both predominantly white samples. What can be said honestly: a Black adult prescribed clindamycin after a US dental procedure carries the same elevated fatal-reaction risk the Thornhill paper reported. What cannot be said honestly: a Black-specific effect size, because no one has measured one. The rate gap is documented; a Black-specific rate gap is not.
Comments